Shareholders in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) had a terrible week, as shares crashed 27% to US$4.16 in the week since its latest first-quarter results. It wasn't the greatest ...

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral ...